Casp Cancer Research Results

Casp, caspase: Click to Expand ⟱
Source:
Type:
The caspase family of proteases are essential to initiate and execute apoptotic cell death. Targeting caspase pathways by gene therapy or endogenous inhibitors represents a promising therapeutic strategy for cancer.
Caspases are divided into two groups: the initiator caspases (caspase-2, -8, -9 and -10), which are the first to be activated in response to a signal, and the executioner caspases (caspase-3, -6, and -7) that carry out the demolition phase of apoptosis.
Caspases are a cysteine protease that speed up a chemical reaction via pointing their target substrates following an aspartic acid residue.1 They are grouped into apoptotic (caspase-2, 3, 6, 7, 8, 9 and 10) and inflammatory (caspase-1, 4, 5, 11 and 12) mediated caspases.


Scientific Papers found: Click to Expand⟱
810- GAR,  GEM,    Garcinol sensitizes human pancreatic adenocarcinoma cells to gemcitabine in association with microRNA signatures
- in-vitro, PC, NA
TumCP↓, Garcinol synergizes with gemcitabine to inhibit cell proliferation and induce apoptosis
Apoptosis↑,
PARP↝,
VEGF↝,
MMPs↝,
Casp↝,
NF-kB↝,
miR-21↝,

4353- MF,  Chemo,    Pulsed Electromagnetic Field Enhances Doxorubicin-induced Reduction in the Viability of MCF-7 Breast Cancer Cells
- in-vitro, BC, MCF-7
TumCCA↑, PEMF enhances the anticancer activity in DOX-treated MCF-7 breast cancer cells by increasing G1 cell cycle arrest and caspase-dependent apoptosis.
Apoptosis↑, we report that PEMF stimulation enhances the reduction in the cell viability by enhancing cell cycle arrest and apoptosis in MCF-7 breast cancer cells.
eff↑, extremely low frequency (ELF)-EMF can increase the cytotoxic effect of DOX on MCF-7 breast cancer cells compared with treatment with DOX alone
TumCCA↑, we report here that PEMF enhances DOX-induced cell cycle arrest in G1 phase and caspase-dependent apoptosis
Casp↝, PEMF promoted the DOX-induced activation of caspases-8, -9, and -7
p‑CDK2↓, combined treatment with DOX and PEMF produced the further reduction in CDK2 phosphorylation and cyclin E2 expression when compared to treatment with DOX alone
cycE/CCNE↓,
Fas↑, expression of Fas and Bax was elevated to a larger degree in the DOX/PEMF-treated cells than in the DOX-treated cells
BAX↑,
survivin↓, expression of survivin was decreased in the DOX-treated cells and further reduced in the DOX/PEMF-treated cells
Mcl-1↓, Mcl-1 expression was reduced in the DOX/PEMF-treated cells compared to the DOX-treated cells
cl‑PARP↑, increased PARP cleavage was observed in the DOX/PEMF-treated cells
cl‑Casp7↑, caspase-7 was higher in the DOX-treated cells than in the control group and was further higher in the DOX/PEMF-treated cells
cl‑Casp8↑, Cleavage of caspase-8 and -9 were elevated in the DOX-treated cells and increased even more in the DOX/PEMF-treated cells
cl‑Casp9↑,


Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Cell Death

Apoptosis↑, 2,   BAX↑, 1,   Casp↝, 2,   cl‑Casp7↑, 1,   cl‑Casp8↑, 1,   cl‑Casp9↑, 1,   Fas↑, 1,   Mcl-1↓, 1,   survivin↓, 1,  

Transcription & Epigenetics

miR-21↝, 1,  

DNA Damage & Repair

PARP↝, 1,   cl‑PARP↑, 1,  

Cell Cycle & Senescence

p‑CDK2↓, 1,   cycE/CCNE↓, 1,   TumCCA↑, 2,  

Migration

MMPs↝, 1,   TumCP↓, 1,  

Angiogenesis & Vasculature

VEGF↝, 1,  

Immune & Inflammatory Signaling

NF-kB↝, 1,  

Drug Metabolism & Resistance

eff↑, 1,  
Total Targets: 20

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: Casp, caspase
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:443  State#:%  Dir#:4
wNotes=on sortOrder:rid,rpid

 

Home Page